Rolf Larsson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4036729/publications.pdf

Version: 2024-02-01

72	2,871	236612	182168
papers	citations	25 h-index	51 g-index

74	74	74	4589
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nature Medicine, 2011, 17, 1636-1640.	15.2	431
2	Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). International Journal of Cancer, 1992, 50, 177-185.	2.3	211
3	Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments. Nature Communications, 2014, 5, 3295.	5.8	197
4	The fluorometric microculture cytotoxicity assay. Nature Protocols, 2008, 3, 1364-1369.	5.5	193
5	Clonal Variation in Drug and Radiation Response among Glioma-Initiating Cells Is Linked to Proneural-Mesenchymal Transition. Cell Reports, 2016, 17, 2994-3009.	2.9	169
6	Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer. Molecular Cancer Therapeutics, 2015, 14, 1504-1516.	1.9	122
7	Inhibition of proteasome activity, nuclear factor-KB translocation and cell survival by the antialcoholism drug disulfiram. International Journal of Cancer, 2006, 118, 1577-1580.	2.3	111
8	Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer. Journal of Cancer Research and Clinical Oncology, 2013, 139, 2133-2140.	1.2	100
9	Detection of tumor-specific cytotoxic drug activityIN VITRO using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. International Journal of Cancer, 1994, 56, 715-720.	2.3	71
10	Tubing loops as a model for cardiopulmonary bypass circuits: Both the biomaterial and the blood-gas phase interfaces induce complement activation in anin vitro model. Journal of Clinical Immunology, 1996, 16, 222-229.	2.0	68
11	Drug repositioning from bench to bedside: Tumour remission by the antihelmintic drug mebendazole in refractory metastatic colon cancer. Acta OncolÃ³gica, 2014, 53, 427-428.	0.8	67
12	DNA methylation-based subtype prediction for pediatric acute lymphoblastic leukemia. Clinical Epigenetics, 2015, 7, 11.	1.8	66
13	Melflufen - a peptidase-potentiated alkylating agent in clinical trials. Oncotarget, 2017, 8, 66641-66655.	0.8	65
14	Iron chelators target both proliferating and quiescent cancer cells. Scientific Reports, 2016, 6, 38343.	1.6	52
15	Increased levels of plasma cytokines and correlations to organ failure and 30-day mortality in critically ill Covid-19 patients. Cytokine, 2021, 138, 155389.	1.4	50
16	Glioblastoma Cell Malignancy and Drug Sensitivity Are Affected by the Cell of Origin. Cell Reports, 2017, 18, 977-990.	2.9	46
17	Image-Based Screening for the Identification of Novel Proteasome Inhibitors. Journal of Biomolecular Screening, 2007, 12, 203-210.	2.6	43
18	Identification of a Novel Topoisomerase Inhibitor Effective in Cells Overexpressing Drug Efflux Transporters. PLoS ONE, 2009, 4, e7238.	1.1	39

#	Article	IF	Citations
19	Pharmacological modification of multi-drug resistance (mdr)in vitro detected by a novel fluorometric microculture cytotoxicity assay. Reversal of resistance and selective cytotoxic actions of cyclosporin a and verapamil on mdr leukemia t-cells. International Journal of Cancer, 1990, 46, 67-72.	2.3	34
20	A PDMS-based disposable microfluidic sensor for CD4+ lymphocyte counting. Biomedical Microdevices, 2008, 10, 851-857.	1.4	34
21	Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia. British Journal of Haematology, 2003, 122, 376-385.	1.2	33
22	In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues. Cancer Chemotherapy and Pharmacology, 2012, 69, 697-707.	1.1	33
23	Large-Scale Gene Expression Profiling Platform for Identification of Context-Dependent Drug Responses in Multicellular Tumor Spheroids. Cell Chemical Biology, 2016, 23, 1428-1438.	2.5	32
24	In vitro determination of cytotoxic drug response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). , 1997, 72, 1008-1012.		30
25	Ex Vivo Assessment of Drug Activity in Patient Tumor Cells as a Basis for Tailored Cancer Therapy. Journal of the Association for Laboratory Automation, 2016, 21, 178-187.	2.8	28
26	Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia. European Journal of Haematology, 2008, 81, 344-353.	1.1	26
27	Mass spectrometry based metabolomics for in vitro systems pharmacology: pitfalls, challenges, and computational solutions. Metabolomics, 2017, 13, 79.	1.4	25
28	Development of vincristine resistance and increased sensitivity to cyclosporin A and verapamil in the human U-937 lymphoma cell line without overexpression of the 170-KDa P-glycoprotein. International Journal of Cancer, 1994, 58, 269-274.	2.3	24
29	Differential activity of cremophor EL and paclitaxel in patients' tumor cells and human carcinoma cell lines in vitro. , 1997, 79, 1225-1233.		24
30	Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy. Journal of Experimental and Clinical Cancer Research, 2014, 33, 110.	3.5	23
31	The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation. Immunopharmacology and Immunotoxicology, 2017, 39, 199-210.	1.1	23
32	Differentialin vitro sensitivity of human tumor and normal cells to chemotherapeutic agents and resistance modulators. International Journal of Cancer, 1991, 48, 598-604.	2.3	22
33	Predictive Value of Ex Vivo Chemosensitivity Assays for Individualized Cancer Chemotherapy: A Meta-Analysis. SLAS Technology, 2017, 22, 306-314.	1.0	22
34	Mesenchymal transition and increased therapy resistance of glioblastoma cells is related to astrocyte reactivity. Journal of Pathology, 2019, 249, 295-307.	2.1	22
35	The FMCA-GM assays, high throughput non-clonogenic alternatives to CFU-GM in preclinical hematotoxicity testing. Toxicology Letters, 2010, 194, 102-107.	0.4	21
36	Targeting tumor cells based on Phosphodiesterase 3A expression. Experimental Cell Research, 2017, 361, 308-315.	1.2	21

#	Article	IF	Citations
37	Gambogic acid is cytotoxic to cancer cells through inhibition of the ubiquitin-proteasome system. Investigational New Drugs, 2013, 31, 587-598.	1.2	19
38	A Pragmatic Definition of Therapeutic Synergy Suitable for Clinically Relevant In Vitro Multicompound Analyses. Molecular Cancer Therapeutics, 2014, 13, 1964-1976.	1.9	16
39	Towards repositioning of quinacrine for treatment of acute myeloid leukemia â€“ Promising synergies and in vivo effects. Leukemia Research, 2017, 63, 41-46.	0.4	16
40	Mebendazole stimulates CD14+ myeloid cells to enhance T-cell activation and tumour cell killing. Oncotarget, 2018, 9, 30805-30813.	0.8	16
41	Cytotoxic activity of topoisomerase II inhibitors in primary cultures of tumor cells from patients with human hematologic and solid tumors. Cancer, 1994, 74, 2857-2862.	2.0	15
42	Mouse Models of Pediatric Supratentorial High-grade Glioma Reveal How Cell-of-Origin Influences Tumor Development and Phenotype. Cancer Research, 2017, 77, 802-812.	0.4	15
43	Preclinical activity of melflufen (J1) in ovarian cancer. Oncotarget, 2016, 7, 59322-59335.	0.8	13
44	AKN-028 induces cell cycle arrest, downregulation of Myc associated genes and dose dependent reduction of tyrosine kinase activity in acute myeloid leukemia. Biochemical Pharmacology, 2014, 87, 284-291.	2.0	12
45	Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition. BMC Research Notes, 2019, 12, 234.	0.6	12
46	Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity. Oncotarget, 2017, 8, 30217-30234.	0.8	12
47	Selective sensitivity of solid tumors to suramin in primary cultures of tumor cells from patients. International Journal of Cancer, 1995, 63, 356-360.	2.3	11
48	In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia. Oncotarget, 2017, 8, 6341-6352.	0.8	11
49	Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism. Oncotarget, 2017, 8, 103952-103967.	0.8	11
50	Mebendazole is unique among tubulin-active drugs in activating the MEKâ€“ERK pathway. Scientific Reports, 2020, 10, 13124.	1.6	9
51	In vitro analysis of drug resistance in tumor cells from patients with acute myelocytic leukemia. Medical Oncology and Tumor Pharmacotherapy, 1992, 9, 65-74.	1.0	9
52	Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma. Scientific Reports, 2022, 12, .	1.6	9
53	Isopedopeptins Aâ€“H: Cationic Cyclic Lipodepsipeptides from Pedobacter cryoconitis UP508 Targeting WHO Top-Priority Carbapenem-Resistant Bacteria. ACS Chemical Biology, 2020, 15, 2937-2944.	1.6	8
54	Descriptive Proteome Analysis to Investigate Context-Dependent Treatment Responses to OXPHOS Inhibition in Colon Carcinoma Cells Grown as Monolayer and Multicellular Tumor Spheroids. ACS Omega, 2020, 5, 17242-17254.	1.6	8

#	Article	IF	Citations
55	Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093789.	1.4	8
56	DNA Methylation Signatures Predict Cytogenetic Subtype and Outcome in Pediatric Acute Myeloid Leukemia (AML). Genes, 2021, 12, 895.	1.0	8
57	Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance. BMC Cancer, 2013, 13, 374.	1.1	7
58	Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei. Annals of Surgical Oncology, 2015, 22, 810-816.	0.7	7
59	A novel tumor spheroid model identifies selective enhancement of radiation by an inhibitor of oxidative phosphorylation. Oncotarget, 2019, 10, 5372-5382.	0.8	7
60	Effects of Calcium Channel Modulators on the Regulation of Cytoplasmic Ca²⁺ and Hormone Secretion of Parathyroid Cells. Basic and Clinical Pharmacology and Toxicology, 1996, 78, 147-153.	0.0	6
61	Detection of Cell Aggregation and Altered Cell Viability by Automated Label-Free Video Microscopy: A Promising Alternative to Endpoint Viability Assays in High-Throughput Screening. Journal of Biomolecular Screening, 2015, 20, 372-381.	2.6	6
62	Pharmacodynamic differences between species exemplified by the novel anticancer agent CHS 828. Drug Development Research, 2004, 61, 218-226.	1.4	4
63	Identification of an inhibitor of the ubiquitinâ€“proteasome system that induces accumulation of polyubiquitinated proteins in the absence of blocking of proteasome function. MedChemComm, 2014, 5, 376-385.	3.5	4
64	Rational Design of Azastatin as a Potential ADC Payload with Reduced Bystander Killing. ChemMedChem, 2020, 15, 2500-2512.	1.6	4
65	Label-free detection and dynamic monitoring of drug-induced intracellular vesicle formation enabled using a 2-dimensional matched filter. Autophagy, 2014, 10, 57-69.	4.3	3
66	Antibacterial pyrrolidinyl and piperidinyl substituted 2,4-diacetylphloroglucinols from Pseudomonas protegens UP46. Journal of Antibiotics, 2020, 73, 739-747.	1.0	3
67	CHS 828 Inhibits Neuroblastoma Growth in Mice Alone and in Combination with Antiangiogenic Drugs. , 0, .		2
68	Ex vivo activity of cytotoxic drugs and targeted agents in small intestinal neuroendocrine tumors. Endocrine-Related Cancer, 2018, 25, 471-480.	1.6	1
69	Selective radiosensitization by nitazoxanide of quiescent clonogenic colon cancer tumour cells. Oncology Letters, 2022, 23, 123.	0.8	1
70	Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes. Bone Reports, 2021, 15, 101098.	0.2	0
71	AKN-028, a FLT-3 Kinase Inhibitor In Preclinical Development, Induces Significant Gene Regulation That Differs From PKC-412. Blood, 2010, 116, 1837-1837.	0.6	0
72	Anti-Myeloma Drug Melflufen Inhibits RANKL-Stimulated Osteoclastogenesis By Suppressing Proliferation of CD14+ Precursor Cells. Blood, 2020, 136, 23-23.	0.6	0